The Authors’ Reply

David R. Head(University of Southern California), James Avakian(University of Utah), Lizardo Cerezo(Orlando Regional Medical Center), Carl R. Kjeldsberg(University of Oklahoma Health Sciences Center)

American Journal of Clinical Pathology

April 1, 1989

10.1093/ajcp/91.4.500

Cited by 0

Related Papers

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

|Blood|2000|1.6k

Age and acute myeloid leukemia

|Blood|2006|1.4k

Acute Myeloid Leukemia in the Elderly: Assessment of Multidrug Resistance (MDR1) and Cytogenetics Distinguishes Biologic Subgroups With Remarkably Distinct Responses to Standard Chemotherapy. A Southwest Oncology Group Study

|Blood|1997|869

Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia.

|Journal of Clinical Oncology|1990|786

Acute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic Leukemia

|New England Journal of Medicine|1991|722